Kytopen is an MIT startup developing their proprietary Flowfect^TM technology for non-viral delivery of molecules into hard-to-transfect immune cells. The scalable Flowfect^TM technology combines microfluidics and automation to make this process easier, faster, and cheaper than ever before. With our automated cell engineering platform we plan to enable new discoveries in biology that will lead to cost effective cell and gene therapies.

Dr. Paulo A. Garcia co-invented the Flowfect™ technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.

Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.

James Hemphill, Ph.D. is a genetic engineer focused on building new functionality into human cells for therapeutic application. He received his Ph.D. in chemical biology from the University of Pittsburgh and has experience in platform development for adoptive cell therapy.

Jessica M. Sido, Ph.D. graduated from the University of South Carolina School of Medicine where she worked on T cell driven inflammatory responses. She recently completed her postdoctoral research in cancer immunology at Harvard Medical School and Dana-Farber Cancer Institute.

Rameech McCormack, M.S. master’s graduate from the Mechanical Engineering Department at MIT. He is also a co-inventor of the high throughput Flowfect™ technology. Rameech leads the effort in product manufacturing, design, and integration.

Kytopen is developing platforms to accelerate the discovery and manufacturing of cell therapies. The Flowfect^TM technology offers a scalable, non-viral solution to deliver genetic payloads to cells in order to augment their functionality. The technology also enables continuous flow genetic manipulation of cells in a platform that can be easily automated and can be used to process both small and large sample volumes.

We are integrating our technology with automated liquid handling systems and developing a large volume platform for therapeutic applications. The non-viral Flowfect^TM solution will reduce the cost and accelerate time to market for discovering and manufacturing next-generation cell and gene therapies.